| Literature DB >> 31974473 |
Sarah Ouahoud1, Philip W Voorneveld1, Lukas J A C Hawinkels1, James C H Hardwick2, Lennart R A van der Burg1, Eveline S M de Jonge-Muller1, Mark J A Schoonderwoerd1, Madelon Paauwe1, Thijs de Vos1, Sophie de Wit1, Gabi W van Pelt3, Wilma E Mesker3.
Abstract
Patients with the mesenchymal subtype colorectal cancer (CRC) have a poor prognosis, in particular patients with stroma-rich tumors and aberrant SMAD4 expression. We hypothesized that interactions between SMAD4-deficient CRC cells and cancer-associated fibroblasts provide a biological explanation. In transwell invasion assays, fibroblasts increased the invasive capacity of SMAD4-deficient HT29 CRC cells, but not isogenic SMAD4-proficient HT29 cells. A TGF-β/BMP-specific array showed BMP2 upregulation by fibroblasts upon stimulation with conditioned medium from SMAD4-deficient CRC cells, while also stimulating their invasion. In a mouse model for experimental liver metastasis, the co-injection of fibroblasts increased metastasis formation of SMAD4-deficient CRC cells (p = 0.02) but not that of SMAD4-proficient CRC cells. Significantly less metastases were seen in mice co-injected with BMP2 knocked-down fibroblasts. Fibroblast BMP2 expression seemed to be regulated by TRAIL, a factor overexpressed in SMAD4-deficient CRC cells. In a cohort of 146 stage III CRC patients, we showed that patients with a combination of high stromal BMP2 expression and the loss of tumor SMAD4 expression had a significantly poorer overall survival (HR 2.88, p = 0.04). Our results suggest the existence of a reciprocal loop in which TRAIL from SMAD4-deficient CRC cells induces BMP2 in fibroblasts, which enhances CRC invasiveness and metastasis.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31974473 DOI: 10.1038/s41388-020-1157-z
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867